Comments on: 5 Big Things To Expect From The FDA Hearings Next Week http://blog.ogilvypr.com/2009/11/5-big-things-to-expect-from-the-fda-hearings-next-week/ An Exploration of What Influences Us Tue, 16 Mar 2010 05:03:13 +0000 http://wordpress.org/?v=2.7 hourly 1 By: Maria Patey http://blog.ogilvypr.com/2009/11/5-big-things-to-expect-from-the-fda-hearings-next-week/comment-page-1/#comment-49788 Maria Patey Thu, 12 Nov 2009 10:16:44 +0000 http://blog.ogilvypr.com/?p=2792#comment-49788 Finally, this is an issue which has been somewhat 'muddy' for such a long time. From a UK perspective we hope the ABPI will embrace some of the outcomes of the hearing to enable clearer guidance with regards to the use of social media for presciption medicines. From a broader communications perspective, the global reach which is enabled by the web, is likely to mean internal communications between 'global' and 'local' marketing teams, becomes a leaner, more streamlined in approach, and one in which everybody must be engaged. We certainly will be monitoring the hearing online. Thank you for posting the URL. Finally, this is an issue which has been somewhat ‘muddy’ for such a long time. From a UK perspective we hope the ABPI will embrace some of the outcomes of the hearing to enable clearer guidance with regards to the use of social media for presciption medicines. From a broader communications perspective, the global reach which is enabled by the web, is likely to mean internal communications between ‘global’ and ‘local’ marketing teams, becomes a leaner, more streamlined in approach, and one in which everybody must be engaged. We certainly will be monitoring the hearing online. Thank you for posting the URL.

]]> By: Nick Peters http://blog.ogilvypr.com/2009/11/5-big-things-to-expect-from-the-fda-hearings-next-week/comment-page-1/#comment-49758 Nick Peters Mon, 09 Nov 2009 16:36:43 +0000 http://blog.ogilvypr.com/?p=2792#comment-49758 Like you, as consultants we are very interested in how the FDA proceeds. Already some of our pharma clients have asked our advice. There are lots of questions to be answered, as we note in our blog posting at http://www.commcoreconsulting.com/blog: Will regulated pharma and medical device companies be allowed to use social media to promote their products and services if, for example, the CDC uses social media to issue alerts and inform the public? Will any FDA regs be flexible enough to accomodate the extraordinary pace of technological innovation in social media? What responsibility will health-related organizations using social media bear once their postings proliferate out of their control? No wonder this hearing is such a hot ticket. It can be monitored online, by the way, via the FDA webcast URL at http://www.fdalive.com/webcast.cfm. Like you, as consultants we are very interested in how the FDA proceeds. Already some of our pharma clients have asked our advice. There are lots of questions to be answered, as we note in our blog posting at http://www.commcoreconsulting.com/blog: Will regulated pharma and medical device companies be allowed to use social media to promote their products and services if, for example, the CDC uses social media to issue alerts and inform the public? Will any FDA regs be flexible enough to accomodate the extraordinary pace of technological innovation in social media? What responsibility will health-related organizations using social media bear once their postings proliferate out of their control?

No wonder this hearing is such a hot ticket. It can be monitored online, by the way, via the FDA webcast URL at http://www.fdalive.com/webcast.cfm.

]]>